Medical Care
Global Systemic Amyloidosis Market Research Report 2025
- Jul 08, 25
- ID: 347587
- Pages: 89
- Figures: 84
- Views: 1
The global market for Systemic Amyloidosis was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Amyloidosis is a clinical disorder caused by extracellular or intracellular deposition of insoluble abnormal amyloid fibrils that affect the normal function of tissues.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Systemic Amyloidosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Amyloidosis.
The Systemic Amyloidosis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Systemic Amyloidosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Amyloidosis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Celgene Corporation(Bristol-Myers Squibb)
Prothena Corporation PLC
TheraPharm Deutschland GmbH
Johnson & Johnson
Amgen Inc.
Onclave Therapeutics Limited
Pfizer Inc.
GlaxoSmithKline plc
Alnylam Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Allergan plc
AbbVie Inc.
Segment by Type
Primary Systemic Amyloidosis (PSA)
Secondary Systemic Amyloidosis
Others
Segment by Application
Hospitals
Clinics
Research Institutes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Systemic Amyloidosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Amyloidosis is a clinical disorder caused by extracellular or intracellular deposition of insoluble abnormal amyloid fibrils that affect the normal function of tissues.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Systemic Amyloidosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Amyloidosis.
The Systemic Amyloidosis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Systemic Amyloidosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Amyloidosis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Celgene Corporation(Bristol-Myers Squibb)
Prothena Corporation PLC
TheraPharm Deutschland GmbH
Johnson & Johnson
Amgen Inc.
Onclave Therapeutics Limited
Pfizer Inc.
GlaxoSmithKline plc
Alnylam Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Allergan plc
AbbVie Inc.
Segment by Type
Primary Systemic Amyloidosis (PSA)
Secondary Systemic Amyloidosis
Others
Segment by Application
Hospitals
Clinics
Research Institutes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Systemic Amyloidosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Amyloidosis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Primary Systemic Amyloidosis (PSA)
1.2.3 Secondary Systemic Amyloidosis
1.2.4 Others
1.3 Market by Application
1.3.1 Global Systemic Amyloidosis Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Systemic Amyloidosis Market Perspective (2020-2031)
2.2 Global Systemic Amyloidosis Growth Trends by Region
2.2.1 Global Systemic Amyloidosis Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Systemic Amyloidosis Historic Market Size by Region (2020-2025)
2.2.3 Systemic Amyloidosis Forecasted Market Size by Region (2026-2031)
2.3 Systemic Amyloidosis Market Dynamics
2.3.1 Systemic Amyloidosis Industry Trends
2.3.2 Systemic Amyloidosis Market Drivers
2.3.3 Systemic Amyloidosis Market Challenges
2.3.4 Systemic Amyloidosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Amyloidosis Players by Revenue
3.1.1 Global Top Systemic Amyloidosis Players by Revenue (2020-2025)
3.1.2 Global Systemic Amyloidosis Revenue Market Share by Players (2020-2025)
3.2 Global Systemic Amyloidosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Systemic Amyloidosis Revenue
3.4 Global Systemic Amyloidosis Market Concentration Ratio
3.4.1 Global Systemic Amyloidosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Amyloidosis Revenue in 2024
3.5 Global Key Players of Systemic Amyloidosis Head office and Area Served
3.6 Global Key Players of Systemic Amyloidosis, Product and Application
3.7 Global Key Players of Systemic Amyloidosis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Systemic Amyloidosis Breakdown Data by Type
4.1 Global Systemic Amyloidosis Historic Market Size by Type (2020-2025)
4.2 Global Systemic Amyloidosis Forecasted Market Size by Type (2026-2031)
5 Systemic Amyloidosis Breakdown Data by Application
5.1 Global Systemic Amyloidosis Historic Market Size by Application (2020-2025)
5.2 Global Systemic Amyloidosis Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Systemic Amyloidosis Market Size (2020-2031)
6.2 North America Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Systemic Amyloidosis Market Size by Country (2020-2025)
6.4 North America Systemic Amyloidosis Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Systemic Amyloidosis Market Size (2020-2031)
7.2 Europe Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Systemic Amyloidosis Market Size by Country (2020-2025)
7.4 Europe Systemic Amyloidosis Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Systemic Amyloidosis Market Size (2020-2031)
8.2 Asia-Pacific Systemic Amyloidosis Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Systemic Amyloidosis Market Size by Region (2020-2025)
8.4 Asia-Pacific Systemic Amyloidosis Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Systemic Amyloidosis Market Size (2020-2031)
9.2 Latin America Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Systemic Amyloidosis Market Size by Country (2020-2025)
9.4 Latin America Systemic Amyloidosis Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Amyloidosis Market Size (2020-2031)
10.2 Middle East & Africa Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Systemic Amyloidosis Market Size by Country (2020-2025)
10.4 Middle East & Africa Systemic Amyloidosis Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene Corporation(Bristol-Myers Squibb)
11.1.1 Celgene Corporation(Bristol-Myers Squibb) Company Details
11.1.2 Celgene Corporation(Bristol-Myers Squibb) Business Overview
11.1.3 Celgene Corporation(Bristol-Myers Squibb) Systemic Amyloidosis Introduction
11.1.4 Celgene Corporation(Bristol-Myers Squibb) Revenue in Systemic Amyloidosis Business (2020-2025)
11.1.5 Celgene Corporation(Bristol-Myers Squibb) Recent Development
11.2 Prothena Corporation PLC
11.2.1 Prothena Corporation PLC Company Details
11.2.2 Prothena Corporation PLC Business Overview
11.2.3 Prothena Corporation PLC Systemic Amyloidosis Introduction
11.2.4 Prothena Corporation PLC Revenue in Systemic Amyloidosis Business (2020-2025)
11.2.5 Prothena Corporation PLC Recent Development
11.3 TheraPharm Deutschland GmbH
11.3.1 TheraPharm Deutschland GmbH Company Details
11.3.2 TheraPharm Deutschland GmbH Business Overview
11.3.3 TheraPharm Deutschland GmbH Systemic Amyloidosis Introduction
11.3.4 TheraPharm Deutschland GmbH Revenue in Systemic Amyloidosis Business (2020-2025)
11.3.5 TheraPharm Deutschland GmbH Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Systemic Amyloidosis Introduction
11.4.4 Johnson & Johnson Revenue in Systemic Amyloidosis Business (2020-2025)
11.4.5 Johnson & Johnson Recent Development
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Details
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Systemic Amyloidosis Introduction
11.5.4 Amgen Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.5.5 Amgen Inc. Recent Development
11.6 Onclave Therapeutics Limited
11.6.1 Onclave Therapeutics Limited Company Details
11.6.2 Onclave Therapeutics Limited Business Overview
11.6.3 Onclave Therapeutics Limited Systemic Amyloidosis Introduction
11.6.4 Onclave Therapeutics Limited Revenue in Systemic Amyloidosis Business (2020-2025)
11.6.5 Onclave Therapeutics Limited Recent Development
11.7 Pfizer Inc.
11.7.1 Pfizer Inc. Company Details
11.7.2 Pfizer Inc. Business Overview
11.7.3 Pfizer Inc. Systemic Amyloidosis Introduction
11.7.4 Pfizer Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.7.5 Pfizer Inc. Recent Development
11.8 GlaxoSmithKline plc
11.8.1 GlaxoSmithKline plc Company Details
11.8.2 GlaxoSmithKline plc Business Overview
11.8.3 GlaxoSmithKline plc Systemic Amyloidosis Introduction
11.8.4 GlaxoSmithKline plc Revenue in Systemic Amyloidosis Business (2020-2025)
11.8.5 GlaxoSmithKline plc Recent Development
11.9 Alnylam Pharmaceuticals, Inc.
11.9.1 Alnylam Pharmaceuticals, Inc. Company Details
11.9.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.9.3 Alnylam Pharmaceuticals, Inc. Systemic Amyloidosis Introduction
11.9.4 Alnylam Pharmaceuticals, Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.9.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Company Details
11.10.2 Takeda Pharmaceutical Company Limited Business Overview
11.10.3 Takeda Pharmaceutical Company Limited Systemic Amyloidosis Introduction
11.10.4 Takeda Pharmaceutical Company Limited Revenue in Systemic Amyloidosis Business (2020-2025)
11.10.5 Takeda Pharmaceutical Company Limited Recent Development
11.11 Allergan plc
11.11.1 Allergan plc Company Details
11.11.2 Allergan plc Business Overview
11.11.3 Allergan plc Systemic Amyloidosis Introduction
11.11.4 Allergan plc Revenue in Systemic Amyloidosis Business (2020-2025)
11.11.5 Allergan plc Recent Development
11.12 AbbVie Inc.
11.12.1 AbbVie Inc. Company Details
11.12.2 AbbVie Inc. Business Overview
11.12.3 AbbVie Inc. Systemic Amyloidosis Introduction
11.12.4 AbbVie Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.12.5 AbbVie Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Amyloidosis Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Primary Systemic Amyloidosis (PSA)
1.2.3 Secondary Systemic Amyloidosis
1.2.4 Others
1.3 Market by Application
1.3.1 Global Systemic Amyloidosis Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Systemic Amyloidosis Market Perspective (2020-2031)
2.2 Global Systemic Amyloidosis Growth Trends by Region
2.2.1 Global Systemic Amyloidosis Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Systemic Amyloidosis Historic Market Size by Region (2020-2025)
2.2.3 Systemic Amyloidosis Forecasted Market Size by Region (2026-2031)
2.3 Systemic Amyloidosis Market Dynamics
2.3.1 Systemic Amyloidosis Industry Trends
2.3.2 Systemic Amyloidosis Market Drivers
2.3.3 Systemic Amyloidosis Market Challenges
2.3.4 Systemic Amyloidosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Amyloidosis Players by Revenue
3.1.1 Global Top Systemic Amyloidosis Players by Revenue (2020-2025)
3.1.2 Global Systemic Amyloidosis Revenue Market Share by Players (2020-2025)
3.2 Global Systemic Amyloidosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Systemic Amyloidosis Revenue
3.4 Global Systemic Amyloidosis Market Concentration Ratio
3.4.1 Global Systemic Amyloidosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Amyloidosis Revenue in 2024
3.5 Global Key Players of Systemic Amyloidosis Head office and Area Served
3.6 Global Key Players of Systemic Amyloidosis, Product and Application
3.7 Global Key Players of Systemic Amyloidosis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Systemic Amyloidosis Breakdown Data by Type
4.1 Global Systemic Amyloidosis Historic Market Size by Type (2020-2025)
4.2 Global Systemic Amyloidosis Forecasted Market Size by Type (2026-2031)
5 Systemic Amyloidosis Breakdown Data by Application
5.1 Global Systemic Amyloidosis Historic Market Size by Application (2020-2025)
5.2 Global Systemic Amyloidosis Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Systemic Amyloidosis Market Size (2020-2031)
6.2 North America Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Systemic Amyloidosis Market Size by Country (2020-2025)
6.4 North America Systemic Amyloidosis Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Systemic Amyloidosis Market Size (2020-2031)
7.2 Europe Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Systemic Amyloidosis Market Size by Country (2020-2025)
7.4 Europe Systemic Amyloidosis Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Systemic Amyloidosis Market Size (2020-2031)
8.2 Asia-Pacific Systemic Amyloidosis Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Systemic Amyloidosis Market Size by Region (2020-2025)
8.4 Asia-Pacific Systemic Amyloidosis Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Systemic Amyloidosis Market Size (2020-2031)
9.2 Latin America Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Systemic Amyloidosis Market Size by Country (2020-2025)
9.4 Latin America Systemic Amyloidosis Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Amyloidosis Market Size (2020-2031)
10.2 Middle East & Africa Systemic Amyloidosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Systemic Amyloidosis Market Size by Country (2020-2025)
10.4 Middle East & Africa Systemic Amyloidosis Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene Corporation(Bristol-Myers Squibb)
11.1.1 Celgene Corporation(Bristol-Myers Squibb) Company Details
11.1.2 Celgene Corporation(Bristol-Myers Squibb) Business Overview
11.1.3 Celgene Corporation(Bristol-Myers Squibb) Systemic Amyloidosis Introduction
11.1.4 Celgene Corporation(Bristol-Myers Squibb) Revenue in Systemic Amyloidosis Business (2020-2025)
11.1.5 Celgene Corporation(Bristol-Myers Squibb) Recent Development
11.2 Prothena Corporation PLC
11.2.1 Prothena Corporation PLC Company Details
11.2.2 Prothena Corporation PLC Business Overview
11.2.3 Prothena Corporation PLC Systemic Amyloidosis Introduction
11.2.4 Prothena Corporation PLC Revenue in Systemic Amyloidosis Business (2020-2025)
11.2.5 Prothena Corporation PLC Recent Development
11.3 TheraPharm Deutschland GmbH
11.3.1 TheraPharm Deutschland GmbH Company Details
11.3.2 TheraPharm Deutschland GmbH Business Overview
11.3.3 TheraPharm Deutschland GmbH Systemic Amyloidosis Introduction
11.3.4 TheraPharm Deutschland GmbH Revenue in Systemic Amyloidosis Business (2020-2025)
11.3.5 TheraPharm Deutschland GmbH Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Systemic Amyloidosis Introduction
11.4.4 Johnson & Johnson Revenue in Systemic Amyloidosis Business (2020-2025)
11.4.5 Johnson & Johnson Recent Development
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Details
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Systemic Amyloidosis Introduction
11.5.4 Amgen Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.5.5 Amgen Inc. Recent Development
11.6 Onclave Therapeutics Limited
11.6.1 Onclave Therapeutics Limited Company Details
11.6.2 Onclave Therapeutics Limited Business Overview
11.6.3 Onclave Therapeutics Limited Systemic Amyloidosis Introduction
11.6.4 Onclave Therapeutics Limited Revenue in Systemic Amyloidosis Business (2020-2025)
11.6.5 Onclave Therapeutics Limited Recent Development
11.7 Pfizer Inc.
11.7.1 Pfizer Inc. Company Details
11.7.2 Pfizer Inc. Business Overview
11.7.3 Pfizer Inc. Systemic Amyloidosis Introduction
11.7.4 Pfizer Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.7.5 Pfizer Inc. Recent Development
11.8 GlaxoSmithKline plc
11.8.1 GlaxoSmithKline plc Company Details
11.8.2 GlaxoSmithKline plc Business Overview
11.8.3 GlaxoSmithKline plc Systemic Amyloidosis Introduction
11.8.4 GlaxoSmithKline plc Revenue in Systemic Amyloidosis Business (2020-2025)
11.8.5 GlaxoSmithKline plc Recent Development
11.9 Alnylam Pharmaceuticals, Inc.
11.9.1 Alnylam Pharmaceuticals, Inc. Company Details
11.9.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.9.3 Alnylam Pharmaceuticals, Inc. Systemic Amyloidosis Introduction
11.9.4 Alnylam Pharmaceuticals, Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.9.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Company Details
11.10.2 Takeda Pharmaceutical Company Limited Business Overview
11.10.3 Takeda Pharmaceutical Company Limited Systemic Amyloidosis Introduction
11.10.4 Takeda Pharmaceutical Company Limited Revenue in Systemic Amyloidosis Business (2020-2025)
11.10.5 Takeda Pharmaceutical Company Limited Recent Development
11.11 Allergan plc
11.11.1 Allergan plc Company Details
11.11.2 Allergan plc Business Overview
11.11.3 Allergan plc Systemic Amyloidosis Introduction
11.11.4 Allergan plc Revenue in Systemic Amyloidosis Business (2020-2025)
11.11.5 Allergan plc Recent Development
11.12 AbbVie Inc.
11.12.1 AbbVie Inc. Company Details
11.12.2 AbbVie Inc. Business Overview
11.12.3 AbbVie Inc. Systemic Amyloidosis Introduction
11.12.4 AbbVie Inc. Revenue in Systemic Amyloidosis Business (2020-2025)
11.12.5 AbbVie Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Systemic Amyloidosis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Primary Systemic Amyloidosis (PSA)
Table 3. Key Players of Secondary Systemic Amyloidosis
Table 4. Key Players of Others
Table 5. Global Systemic Amyloidosis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Systemic Amyloidosis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Systemic Amyloidosis Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Systemic Amyloidosis Market Share by Region (2020-2025)
Table 9. Global Systemic Amyloidosis Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Systemic Amyloidosis Market Share by Region (2026-2031)
Table 11. Systemic Amyloidosis Market Trends
Table 12. Systemic Amyloidosis Market Drivers
Table 13. Systemic Amyloidosis Market Challenges
Table 14. Systemic Amyloidosis Market Restraints
Table 15. Global Systemic Amyloidosis Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Systemic Amyloidosis Market Share by Players (2020-2025)
Table 17. Global Top Systemic Amyloidosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Amyloidosis as of 2024)
Table 18. Ranking of Global Top Systemic Amyloidosis Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Systemic Amyloidosis Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Systemic Amyloidosis, Headquarters and Area Served
Table 21. Global Key Players of Systemic Amyloidosis, Product and Application
Table 22. Global Key Players of Systemic Amyloidosis, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Systemic Amyloidosis Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Systemic Amyloidosis Revenue Market Share by Type (2020-2025)
Table 26. Global Systemic Amyloidosis Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Systemic Amyloidosis Revenue Market Share by Type (2026-2031)
Table 28. Global Systemic Amyloidosis Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Systemic Amyloidosis Revenue Market Share by Application (2020-2025)
Table 30. Global Systemic Amyloidosis Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Systemic Amyloidosis Revenue Market Share by Application (2026-2031)
Table 32. North America Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Systemic Amyloidosis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Systemic Amyloidosis Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Systemic Amyloidosis Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 47. Celgene Corporation(Bristol-Myers Squibb) Company Details
Table 48. Celgene Corporation(Bristol-Myers Squibb) Business Overview
Table 49. Celgene Corporation(Bristol-Myers Squibb) Systemic Amyloidosis Product
Table 50. Celgene Corporation(Bristol-Myers Squibb) Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 51. Celgene Corporation(Bristol-Myers Squibb) Recent Development
Table 52. Prothena Corporation PLC Company Details
Table 53. Prothena Corporation PLC Business Overview
Table 54. Prothena Corporation PLC Systemic Amyloidosis Product
Table 55. Prothena Corporation PLC Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 56. Prothena Corporation PLC Recent Development
Table 57. TheraPharm Deutschland GmbH Company Details
Table 58. TheraPharm Deutschland GmbH Business Overview
Table 59. TheraPharm Deutschland GmbH Systemic Amyloidosis Product
Table 60. TheraPharm Deutschland GmbH Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 61. TheraPharm Deutschland GmbH Recent Development
Table 62. Johnson & Johnson Company Details
Table 63. Johnson & Johnson Business Overview
Table 64. Johnson & Johnson Systemic Amyloidosis Product
Table 65. Johnson & Johnson Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 66. Johnson & Johnson Recent Development
Table 67. Amgen Inc. Company Details
Table 68. Amgen Inc. Business Overview
Table 69. Amgen Inc. Systemic Amyloidosis Product
Table 70. Amgen Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 71. Amgen Inc. Recent Development
Table 72. Onclave Therapeutics Limited Company Details
Table 73. Onclave Therapeutics Limited Business Overview
Table 74. Onclave Therapeutics Limited Systemic Amyloidosis Product
Table 75. Onclave Therapeutics Limited Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 76. Onclave Therapeutics Limited Recent Development
Table 77. Pfizer Inc. Company Details
Table 78. Pfizer Inc. Business Overview
Table 79. Pfizer Inc. Systemic Amyloidosis Product
Table 80. Pfizer Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 81. Pfizer Inc. Recent Development
Table 82. GlaxoSmithKline plc Company Details
Table 83. GlaxoSmithKline plc Business Overview
Table 84. GlaxoSmithKline plc Systemic Amyloidosis Product
Table 85. GlaxoSmithKline plc Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 86. GlaxoSmithKline plc Recent Development
Table 87. Alnylam Pharmaceuticals, Inc. Company Details
Table 88. Alnylam Pharmaceuticals, Inc. Business Overview
Table 89. Alnylam Pharmaceuticals, Inc. Systemic Amyloidosis Product
Table 90. Alnylam Pharmaceuticals, Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 91. Alnylam Pharmaceuticals, Inc. Recent Development
Table 92. Takeda Pharmaceutical Company Limited Company Details
Table 93. Takeda Pharmaceutical Company Limited Business Overview
Table 94. Takeda Pharmaceutical Company Limited Systemic Amyloidosis Product
Table 95. Takeda Pharmaceutical Company Limited Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 96. Takeda Pharmaceutical Company Limited Recent Development
Table 97. Allergan plc Company Details
Table 98. Allergan plc Business Overview
Table 99. Allergan plc Systemic Amyloidosis Product
Table 100. Allergan plc Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 101. Allergan plc Recent Development
Table 102. AbbVie Inc. Company Details
Table 103. AbbVie Inc. Business Overview
Table 104. AbbVie Inc. Systemic Amyloidosis Product
Table 105. AbbVie Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 106. AbbVie Inc. Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
Table 110. Authors List of This Report
List of Figures
Figure 1. Systemic Amyloidosis Picture
Figure 2. Global Systemic Amyloidosis Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Systemic Amyloidosis Market Share by Type: 2024 VS 2031
Figure 4. Primary Systemic Amyloidosis (PSA) Features
Figure 5. Secondary Systemic Amyloidosis Features
Figure 6. Others Features
Figure 7. Global Systemic Amyloidosis Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Systemic Amyloidosis Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Research Institutes Case Studies
Figure 12. Others Case Studies
Figure 13. Systemic Amyloidosis Report Years Considered
Figure 14. Global Systemic Amyloidosis Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Systemic Amyloidosis Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Systemic Amyloidosis Market Share by Region: 2024 VS 2031
Figure 17. Global Systemic Amyloidosis Market Share by Players in 2024
Figure 18. Global Top Systemic Amyloidosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Amyloidosis as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Systemic Amyloidosis Revenue in 2024
Figure 20. North America Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 22. United States Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 26. Germany Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Systemic Amyloidosis Market Share by Region (2020-2031)
Figure 34. China Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 42. Mexico Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 46. Turkey Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Celgene Corporation(Bristol-Myers Squibb) Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 50. Prothena Corporation PLC Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 51. TheraPharm Deutschland GmbH Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 52. Johnson & Johnson Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 53. Amgen Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 54. Onclave Therapeutics Limited Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 55. Pfizer Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 56. GlaxoSmithKline plc Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 57. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 58. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 59. Allergan plc Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 60. AbbVie Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Systemic Amyloidosis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Primary Systemic Amyloidosis (PSA)
Table 3. Key Players of Secondary Systemic Amyloidosis
Table 4. Key Players of Others
Table 5. Global Systemic Amyloidosis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Systemic Amyloidosis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Systemic Amyloidosis Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Systemic Amyloidosis Market Share by Region (2020-2025)
Table 9. Global Systemic Amyloidosis Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Systemic Amyloidosis Market Share by Region (2026-2031)
Table 11. Systemic Amyloidosis Market Trends
Table 12. Systemic Amyloidosis Market Drivers
Table 13. Systemic Amyloidosis Market Challenges
Table 14. Systemic Amyloidosis Market Restraints
Table 15. Global Systemic Amyloidosis Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Systemic Amyloidosis Market Share by Players (2020-2025)
Table 17. Global Top Systemic Amyloidosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Amyloidosis as of 2024)
Table 18. Ranking of Global Top Systemic Amyloidosis Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Systemic Amyloidosis Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Systemic Amyloidosis, Headquarters and Area Served
Table 21. Global Key Players of Systemic Amyloidosis, Product and Application
Table 22. Global Key Players of Systemic Amyloidosis, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Systemic Amyloidosis Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Systemic Amyloidosis Revenue Market Share by Type (2020-2025)
Table 26. Global Systemic Amyloidosis Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Systemic Amyloidosis Revenue Market Share by Type (2026-2031)
Table 28. Global Systemic Amyloidosis Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Systemic Amyloidosis Revenue Market Share by Application (2020-2025)
Table 30. Global Systemic Amyloidosis Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Systemic Amyloidosis Revenue Market Share by Application (2026-2031)
Table 32. North America Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Systemic Amyloidosis Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Systemic Amyloidosis Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Systemic Amyloidosis Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Systemic Amyloidosis Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Systemic Amyloidosis Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Systemic Amyloidosis Market Size by Country (2026-2031) & (US$ Million)
Table 47. Celgene Corporation(Bristol-Myers Squibb) Company Details
Table 48. Celgene Corporation(Bristol-Myers Squibb) Business Overview
Table 49. Celgene Corporation(Bristol-Myers Squibb) Systemic Amyloidosis Product
Table 50. Celgene Corporation(Bristol-Myers Squibb) Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 51. Celgene Corporation(Bristol-Myers Squibb) Recent Development
Table 52. Prothena Corporation PLC Company Details
Table 53. Prothena Corporation PLC Business Overview
Table 54. Prothena Corporation PLC Systemic Amyloidosis Product
Table 55. Prothena Corporation PLC Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 56. Prothena Corporation PLC Recent Development
Table 57. TheraPharm Deutschland GmbH Company Details
Table 58. TheraPharm Deutschland GmbH Business Overview
Table 59. TheraPharm Deutschland GmbH Systemic Amyloidosis Product
Table 60. TheraPharm Deutschland GmbH Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 61. TheraPharm Deutschland GmbH Recent Development
Table 62. Johnson & Johnson Company Details
Table 63. Johnson & Johnson Business Overview
Table 64. Johnson & Johnson Systemic Amyloidosis Product
Table 65. Johnson & Johnson Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 66. Johnson & Johnson Recent Development
Table 67. Amgen Inc. Company Details
Table 68. Amgen Inc. Business Overview
Table 69. Amgen Inc. Systemic Amyloidosis Product
Table 70. Amgen Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 71. Amgen Inc. Recent Development
Table 72. Onclave Therapeutics Limited Company Details
Table 73. Onclave Therapeutics Limited Business Overview
Table 74. Onclave Therapeutics Limited Systemic Amyloidosis Product
Table 75. Onclave Therapeutics Limited Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 76. Onclave Therapeutics Limited Recent Development
Table 77. Pfizer Inc. Company Details
Table 78. Pfizer Inc. Business Overview
Table 79. Pfizer Inc. Systemic Amyloidosis Product
Table 80. Pfizer Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 81. Pfizer Inc. Recent Development
Table 82. GlaxoSmithKline plc Company Details
Table 83. GlaxoSmithKline plc Business Overview
Table 84. GlaxoSmithKline plc Systemic Amyloidosis Product
Table 85. GlaxoSmithKline plc Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 86. GlaxoSmithKline plc Recent Development
Table 87. Alnylam Pharmaceuticals, Inc. Company Details
Table 88. Alnylam Pharmaceuticals, Inc. Business Overview
Table 89. Alnylam Pharmaceuticals, Inc. Systemic Amyloidosis Product
Table 90. Alnylam Pharmaceuticals, Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 91. Alnylam Pharmaceuticals, Inc. Recent Development
Table 92. Takeda Pharmaceutical Company Limited Company Details
Table 93. Takeda Pharmaceutical Company Limited Business Overview
Table 94. Takeda Pharmaceutical Company Limited Systemic Amyloidosis Product
Table 95. Takeda Pharmaceutical Company Limited Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 96. Takeda Pharmaceutical Company Limited Recent Development
Table 97. Allergan plc Company Details
Table 98. Allergan plc Business Overview
Table 99. Allergan plc Systemic Amyloidosis Product
Table 100. Allergan plc Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 101. Allergan plc Recent Development
Table 102. AbbVie Inc. Company Details
Table 103. AbbVie Inc. Business Overview
Table 104. AbbVie Inc. Systemic Amyloidosis Product
Table 105. AbbVie Inc. Revenue in Systemic Amyloidosis Business (2020-2025) & (US$ Million)
Table 106. AbbVie Inc. Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
Table 110. Authors List of This Report
List of Figures
Figure 1. Systemic Amyloidosis Picture
Figure 2. Global Systemic Amyloidosis Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Systemic Amyloidosis Market Share by Type: 2024 VS 2031
Figure 4. Primary Systemic Amyloidosis (PSA) Features
Figure 5. Secondary Systemic Amyloidosis Features
Figure 6. Others Features
Figure 7. Global Systemic Amyloidosis Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Systemic Amyloidosis Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Research Institutes Case Studies
Figure 12. Others Case Studies
Figure 13. Systemic Amyloidosis Report Years Considered
Figure 14. Global Systemic Amyloidosis Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Systemic Amyloidosis Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Systemic Amyloidosis Market Share by Region: 2024 VS 2031
Figure 17. Global Systemic Amyloidosis Market Share by Players in 2024
Figure 18. Global Top Systemic Amyloidosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Amyloidosis as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Systemic Amyloidosis Revenue in 2024
Figure 20. North America Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 22. United States Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 26. Germany Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Systemic Amyloidosis Market Share by Region (2020-2031)
Figure 34. China Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 42. Mexico Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Systemic Amyloidosis Market Share by Country (2020-2031)
Figure 46. Turkey Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Systemic Amyloidosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Celgene Corporation(Bristol-Myers Squibb) Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 50. Prothena Corporation PLC Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 51. TheraPharm Deutschland GmbH Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 52. Johnson & Johnson Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 53. Amgen Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 54. Onclave Therapeutics Limited Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 55. Pfizer Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 56. GlaxoSmithKline plc Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 57. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 58. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 59. Allergan plc Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 60. AbbVie Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232